Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer: A population-based study

Keyphrases

• Adherence Rate 25%
• American Cancer Society 25%
• Antiemesis 100%
• Antiemetic Agents 25%
• Antiemetic Prophylaxis 75%
• Antiemetics 25%
• Binary Variables 25%
• Chemotherapy 100%
• Chemotherapy Agents 25%
• Chemotherapy-induced Nausea 50%
• Clinical Consequences 25%
• Clinical Outcomes 25%
• Concurrent Radiation 25%
• Economic Consequences 25%
• Economic Outcomes 25%
• First Diagnosis 25%
• Highly Emetogenic 50%
• Linked Databases 25%
• Logistic Regression 25%
• Logistic Regression Modeling 25%
• Lung Cancer 100%
• Lung Cancer Diagnosis 25%
• Median Income 25%
• Medicare 25%
• Medicare Part A 25%
• Multivariate Logistic Regression 25%
• National Comprehensive Cancer Network 25%
• National Guidelines 100%
• Nausea 50%
• Non-adherent 25%
• Old Age 25%
• Ondansetron 25%
• Patient Adherence 25%
• Patient Characteristics 25%
• Patient Selection 25%
• Platinum-based Chemotherapy 50%
• Population Data 25%
• Population-based Study 100%
• Radiation Therapy 25%
• Recommended Regimen 25%
• Serotonin Antagonists 25%
• Socioeconomic Barriers 25%
• Stepwise Selection 25%
• Substance P 50%
• Texas Cancer Registry 25%
• Vomiting 50%
• White Race 25%

Nursing and Health Professions

• Adherence 100%
• Antiemetic Agent 71%
• Cancer Network 14%
• Cancer Registry 14%
• Chemotherapy 100%
• Chemotherapy Induced Nausea and Vomiting 14%
• Dexamethasone 14%
• Logistic Regression Analysis 28%
• Lung Cancer 100%
• Malignant Neoplasm 14%
• Medicare 28%
• Nausea and Vomiting 28%
• Patient Compliance 14%
• Platinum 28%
• Practice Guideline 100%
• Radiotherapy 14%
• Serotonin Antagonist 14%
• Substance P Antagonist 28%
• Zofran 14%

Medicine and Dentistry

• Antiemetic 83%
• Cancer Registry 16%
• Chemotherapy 100%
• Chemotherapy Agent 16%
• Chemotherapy-Induced Nausea and Vomiting 16%
• Dexamethasone 16%
• Logistic Regression Analysis 33%
• Lung Cancer 100%
• Malignant Neoplasm 50%
• Medicare 33%
• Nausea and Vomiting 33%
• Ondansetron 16%
• Patient Characteristics 16%
• Patient Compliance 16%
• Platinum 33%
• Radiation Therapy 16%
• Serotonin Antagonist 16%
• Substance P Antagonist 33%